Hazel Huang1, Ali Aminian2, Monique Hassan2, Olivia Dan2, Christopher L Axelrod1,3, Philip R Schauer2, Stacy A Brethauer2, John P Kirwan4,5. 1. Department of Pathobiology, Cleveland Clinic, Lerner Research Institute, Cleveland, OH, USA. 2. Cleveland Clinic, Bariatric and Metabolic Institute, Cleveland, OH, USA. 3. Integrated Physiology and Molecular Medicine Laboratory, Pennington Biomedical Research Center, 6400 Perkins Road, L-4030, Baton Rouge, LA, 70808, USA. 4. Department of Pathobiology, Cleveland Clinic, Lerner Research Institute, Cleveland, OH, USA. john.kirwan@pbrc.edu. 5. Integrated Physiology and Molecular Medicine Laboratory, Pennington Biomedical Research Center, 6400 Perkins Road, L-4030, Baton Rouge, LA, 70808, USA. john.kirwan@pbrc.edu.
Abstract
PURPOSE: Roux-en-Y gastric bypass (RYGB) is associated with remission of type 2 diabetes. However, the cellular and molecular mechanisms remain unknown. We hypothesized that RYGB would increase peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α), sirtuin-1 (SIRT1), AMPK/pAMPK, and citrate synthase (CS) protein expression and decrease insulin resistance and these changes would be mediated by sphingolipids, including ceramides and the sphingolipid metabolite sphingosine-1 phosphate (S1P). MATERIALS AND METHODS: Male ZDF rats were randomized to RYGB (n = 7) or sham surgery (n = 7) and harvested after 28 days. Total tissue ceramide, ceramide subspecies (C14:0, C16:0, C18:0, C18:1, C20:0, C24:0, and C24:1), and S1P were quantified in the white gastrocnemius muscle using LC-ESI-MS/MS after separation with HPLC. Total SIRT1, AMPK, PGC-1α, and CS protein expression were measured by Western blot. RESULTS: Body weight, fasting glucose, insulin, and HOMA-IR decreased significantly after RYGB compared with sham control. These changes were paralleled by lower total ceramide (483.7 ± 32.3 vs. 280.1 ± 38.8 nmol/g wwt), C18:0 ceramide subspecies (P < 0.05), higher S1P (0.83 ± 0.05 vs. 1.54 ± 0.21 nmol/g wwt, P < 0.05), and a lower ceramide/S1P ratio (P < 0.05) in the RYGB versus sham group. AMPK, pAMPK, SIRT1, PGC-1α, and CS protein expression was also higher after RYGB (P < 0.05). The ceramide/S1P ratio correlated with weight loss (r = 0.48, P = 0.08), insulin resistance (r = 0.61, P = 0.02), PGC-1α (r = - 0.51, P < 0.06), CS (r = - 0.63, P = 0.01), and SIRT1 (r = - 0.54, P < 0.04). CONCLUSION: Our data demonstrate that sphingolipid balance, and increased AMPK, SIRT1, PGC-1α, and CS protein expression are part of the mechanism that contributes to the remission of diabetes after RYGB surgery.
PURPOSE: Roux-en-Y gastric bypass (RYGB) is associated with remission of type 2 diabetes. However, the cellular and molecular mechanisms remain unknown. We hypothesized that RYGB would increase peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α), sirtuin-1 (SIRT1), AMPK/pAMPK, and citrate synthase (CS) protein expression and decrease insulin resistance and these changes would be mediated by sphingolipids, including ceramides and the sphingolipid metabolite sphingosine-1 phosphate (S1P). MATERIALS AND METHODS: Male ZDFrats were randomized to RYGB (n = 7) or sham surgery (n = 7) and harvested after 28 days. Total tissue ceramide, ceramide subspecies (C14:0, C16:0, C18:0, C18:1, C20:0, C24:0, and C24:1), and S1P were quantified in the white gastrocnemius muscle using LC-ESI-MS/MS after separation with HPLC. Total SIRT1, AMPK, PGC-1α, and CS protein expression were measured by Western blot. RESULTS: Body weight, fasting glucose, insulin, and HOMA-IR decreased significantly after RYGB compared with sham control. These changes were paralleled by lower total ceramide (483.7 ± 32.3 vs. 280.1 ± 38.8 nmol/g wwt), C18:0 ceramide subspecies (P < 0.05), higher S1P (0.83 ± 0.05 vs. 1.54 ± 0.21 nmol/g wwt, P < 0.05), and a lower ceramide/S1P ratio (P < 0.05) in the RYGB versus sham group. AMPK, pAMPK, SIRT1, PGC-1α, and CS protein expression was also higher after RYGB (P < 0.05). The ceramide/S1P ratio correlated with weight loss (r = 0.48, P = 0.08), insulin resistance (r = 0.61, P = 0.02), PGC-1α (r = - 0.51, P < 0.06), CS (r = - 0.63, P = 0.01), and SIRT1 (r = - 0.54, P < 0.04). CONCLUSION: Our data demonstrate that sphingolipid balance, and increased AMPK, SIRT1, PGC-1α, and CS protein expression are part of the mechanism that contributes to the remission of diabetes after RYGB surgery.
Authors: Stacy A Brethauer; Ali Aminian; Héctor Romero-Talamás; Esam Batayyah; Jennifer Mackey; Laurence Kennedy; Sangeeta R Kashyap; John P Kirwan; Tomasz Rogula; Matthew Kroh; Bipan Chand; Philip R Schauer Journal: Ann Surg Date: 2013-10 Impact factor: 12.969
Authors: Philip R Schauer; Deepak L Bhatt; John P Kirwan; Kathy Wolski; Ali Aminian; Stacy A Brethauer; Sankar D Navaneethan; Rishi P Singh; Claire E Pothier; Steven E Nissen; Sangeeta R Kashyap Journal: N Engl J Med Date: 2017-02-16 Impact factor: 91.245
Authors: Ethan J Anderson; Mary E Lustig; Kristen E Boyle; Tracey L Woodlief; Daniel A Kane; Chien-Te Lin; Jesse W Price; Li Kang; Peter S Rabinovitch; Hazel H Szeto; Joseph A Houmard; Ronald N Cortright; David H Wasserman; P Darrell Neufer Journal: J Clin Invest Date: 2009-02-02 Impact factor: 14.808
Authors: Henry Buchwald; Rhonda Estok; Kyle Fahrbach; Deirdre Banel; Michael D Jensen; Walter J Pories; John P Bantle; Isabella Sledge Journal: Am J Med Date: 2009-03 Impact factor: 4.965
Authors: Roman Vangoitsenhoven; Rickesha Wilson; Gautam Sharma; Suriya Punchai; Ricard Corcelles; Dvir Froylich; Anny Mulya; Philip R Schauer; Stacy A Brethauer; John P Kirwan; Naseer Sangwan; J Mark Brown; Ali Aminian Journal: Surg Endosc Date: 2020-06-30 Impact factor: 4.584
Authors: Matthew D Barberio; G Lynis Dohm; Walter J Pories; Natalie A Gadaleta; Joseph A Houmard; Evan P Nadler; Monica J Hubal Journal: Front Endocrinol (Lausanne) Date: 2021-10-06 Impact factor: 5.555